Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorJessa Hospital
About this trial
Up to one out of five patients with breast cancer will develop lymphedema in the upper extremity after cancer treatment. Patients with breast cancer-related lymphedema (BCRL) suffer from pain, heaviness, tightness, and a decreased range of motion. Photobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and/or near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. Therefore, the aim of this study is to evaluate the effectiveness of PBMT on the management of BCRL.
Eligibility criteria
Qualifiers
Diagnosed with breast cancer
Underwent ipsilateral lumpectomy or mastectomy + sentinel lymph node biopsy +/- lymph node dissection
Underwent radiotherapy with or without chemotherapy
Diagnosed with BCRL (i.e. International Society of Lymphology (ISL) lymphedema stage I or higher)
Disqualifiers
Metastatic disease
Pregnancy
History of surgery or trauma to the arm
History of arm infection in the past 3 months
Trial design
Treatments tested in this trial
- Photobiomodulation therapy (PBMT)
- Manual Lymphatic drainage
Treatment groups
104 Participants
are divided into 2 treatment groupsSponsors and collaborators
Jessa Hospital
Lead sponsor
Hasselt University
Collaborator
Source ClinicalTrials.gov